| 1 |
34264305 | Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. | 2021 Sep 1 |
2 |
| 2 |
29491076 | COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients. | 2018 Mar |
1 |
| 3 |
28450158 | The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer. | 2017 Aug 1 |
1 |
| 4 |
20480225 | A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. | 2010 Jul |
1 |
| 5 |
19138958 | Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid. | 2008 Aug |
3 |
| 6 |
17285134 | Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. | 2007 Feb 26 |
1 |
| 7 |
16887935 | Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. | 2006 Nov |
1 |
| 8 |
16168126 | Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. | 2005 |
1 |
| 9 |
16373709 | Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. | 2005 Dec |
1 |
| 10 |
15217939 | Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. | 2004 Jun 15 |
2 |
| 11 |
15269135 | Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. | 2004 Jul 15 |
1 |
| 12 |
12359744 | Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. | 2002 Oct 1 |
6 |